Core Insights - The successful development of the "Xingjie Large Model" by Fangzhou Jianke marks a significant advancement in the "AI + Chronic Disease Management" sector, having received official registration from the National Cyberspace Administration of China [1][3] - The model aims to transform traditional passive healthcare services into proactive, personalized solutions driven by AI technology, enhancing user experience and engagement [3][4] Group 1: Model Development and Capabilities - The "Xingjie Large Model" is designed to address complex user needs in chronic disease management, moving beyond simple question-answering to provide comprehensive, one-stop solutions [4] - Key innovations of the model include deep emotional perception and intent reasoning capabilities, enabling it to anticipate user needs and provide timely responses [5] - The model also features a self-evolving knowledge base that learns from documents and historical interactions, significantly reducing maintenance costs and expanding service coverage [5] Group 2: Ecosystem Expansion and Partnerships - Fangzhou Jianke is expanding its "AI + H2H" ecosystem by collaborating with leading pharmaceutical companies such as Novo Nordisk, Innovent Biologics, and Fosun Pharma to create benchmarks in "AI + Specialty Disease Management" [6] - The company has successfully implemented intelligent service loops in specific disease management areas, such as weight management and psoriasis, showcasing the practical value of AI technology [6] Group 3: Strategic Vision and Future Directions - The establishment of the "Xingjie Large Model" as a foundational element of the AI + H2H ecosystem reflects the company's commitment to leveraging technological advancements for chronic disease management [7][9] - Fangzhou Jianke aims to align its innovations with national policies on technological innovation and chronic disease management, contributing to the broader goal of building a healthier China [9]
响应“人工智能+”国家行动，方舟健客“杏捷大模型”通过国家备案，为AI+慢病管理注入新动能